TECHWIRE 30
(CIX: WRAL30)  1,102.96  up arrow+11.29  (1.03 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Apple)  108.00  up arrow+1.02  (0.95 %)  Updated: 06:25 PM EDT, Oct 31 2014
(NY: QUINTILES)  58.54  up arrow+2.24  (3.98 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: BASF SE)  88.22  up arrow+1.3  (1.5 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: BioCryst)  11.72  down arrow-0.34  (-2.82 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: BioDelivery)  17.40  down arrow-0.39  (-2.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: CEMP)  13.60  down arrow-0.09  (-0.66 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Cisco Systems)  24.47  up arrow+0.39  (1.62 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Cree)  31.48  down arrow-0.03  (-0.1 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: DARA)  0.85  down arrow-0.03  (-3.3 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: EMC CORPORATION)  28.73  up arrow+0.27  (0.95 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Extreme Networks)  3.59  up arrow+0.06  (1.7 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: FB)  74.99  up arrow+0.88  (1.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: GLAXOSMITHKLINE)  45.49  up arrow+0.35  (0.78 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: GOOG)  559.08  up arrow+8.77  (1.59 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: IBM)  164.40  up arrow+0.05  (0.03 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NY: LH)  109.29  up arrow+1.9  (1.77 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Lenovo Group)  29.49  down arrow-0.07  (-0.24 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: MRK)  57.94  up arrow+0.63  (1.1 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Microsoft Corp)  46.95  up arrow+0.9  (1.95 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: NTAP)  42.80  up arrow+0.69  (1.64 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: NOVARTIS AG)  92.69  up arrow+0.74  (0.8 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Novozymes A/S)  46.30  down arrow-0.01  (-0.02 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: PFIZER)  29.95  up arrow+0.11  (0.37 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Pozen)  9.07  down arrow-0.1  (-1.09 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: RED HAT)  58.92  up arrow+0.67  (1.15 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: BBRY)  10.50  up arrow+0.02  (0.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Salix)  143.85  down arrow-0.65  (-0.45 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: SQI)  14.91  down arrow-2.02  (-11.93 %)  Updated: 05:20 PM EDT, Oct 31 2014

Posts tagged “Biotech & Life Science”

1:52 p.m. today

RTP pharma firm expanding; CommScope revenues surge; $15M in new business for PowerSecure; LinkedIn posts loss

Bulldog In today's Bulldog wrapup of life science and technology news: RTP-based Cirrus Pharmaceuticals is expanding; CommScope revenues hit $1 billion; PowerSecure books $15 million in new business; and LinkedIn reports a loss.

12:51 p.m. today

Longtime GSK exec Viehbacher ousted as Sanofi CEO

Chris Viehbacher Chris Viehbacher, a longtime GSK executive and triangle resident who lost out in the battle to become CEO of that job giant, has lost his job as CEO at French drugmaker Sanofi.

11:46 a.m. today

RTP startup Benson Hill lands $100,000 USDA grant

Agbio Research Triangle Park agricultural biotechnology startup Benson Hill Biosystems, bootstrapped with an NCBiotech loan in 2012, has been awarded nearly $100,000 by the U.S. Department of Agriculture to pursue its development of enhanced plant productivity.

Updated 6:50 a.m. today

Premium Lock CEO: Look for Quintiles to take more firms 'under our wing'

Quintiles CEO Tom Pike is on the lookout for more acquisitions. In a quarterly earnings conference call Thursday, Pike said the world's largest life science services company is on the "lookout" to put acquisition targets "under our wing." Our Insider subscribers get the details.

Tom Pike Tom Pike

2:16 p.m. yesterday

Red Hat's new 'cloud' startup plan; Microsoft launches 'Health,' fitness band; Google 'tax;' bioMerieux 1-hour Ebola test; ChannelAdvisor adds home improvement

Bulldog In today's Bulldog wrapup of tech and life science news: Red Hat aims to help startups go "cloud;" Microsoft is getting into fitness; Spain passes Google tax; a bioMerieux subsidiary offers 1-hour Ebola test; and ChannelAdvisor adds home improvement to its ecommerce suite.

11:45 a.m. yesterday

Durham-based Chimerix gears up Ebola tests, raising $105M

Ebola Chimerix is gearing up for the FDA- approved to launch a Phase 2 clinical trial of its possible treatment for Ebola. The company also is looking to raise $105 million.

10:00 a.m. yesterday

Premium Lock Quintiles beats Street, ups its earnings forecast

Quintiles        Quintiles meets Wall Street expectations for revenues but tops those same forecasts in earnings by a penny a share. The global life science services firm also ups its earnings forecast.

6:45 a.m. Wednesday

Premium Lock Raleigh-based INC Research raises target price for IPO to $186M

INC Research, a life science services firm based in Raleigh, is looking to raise some $186 million in its IPO. That's more than $30 million higher than the initial target.. INC lost money in 2013 but is in the black so far in 2014, according to its IPO filing.

6:15 a.m. Wednesday

Google working on nanotechnology pill that searches for illnesses

Google is working on a cancer-detecting pill in its latest effort to push the boundaries of technology. Still in the experimental stage, the pill is packed with tiny magnetic particles, which can travel through a patient's bloodstream, search for malignant cells and report their findings to a sensor on a wearable device.

Google Research Google Research

7:18 a.m. Tuesday

Silicon Valley must join the Ebola battle before it becomes a matter of survival

Ebola Opinion: Former Triangle tech entrepreneur Vivek Wadhwa, now an author and academic, issues a call to arms for technology companies to rise to the challenge of fighting Ebola.

2:21 p.m. Monday

Premium Lock WEPPA finds partner to launch new telehealth platform

Wake Emergency Physicians, PA, in partnership with TeleCommunication Systems, are launching the VirtuMedix Telehealth Platform this week at the American College of Emergency Physicians' ACEP14 in Chicago.

VirtuMedix VirtuMedix

6:44 a.m. Monday

Drugmakers bet on Ebola vaccines, treatments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history.

Ebola-Pharma Opportunity Ebola-Pharma Opportunity

Updated 6:32 a.m. Monday

Novartis' Holly Springs plant sold to Australian firm in $275M deal

Drug giant Novartis is selling its $1-billion vaccine production plant in Holly Springs to Australia-based CSL as part of a deal valued at $275 million. Novartis is disposing its entire influenza-related vaccine business through this transaction that was announced Sunday night. Some 550 people work at the Holly Springs facility.

Novartis plant in Holly Springs Novartis plant in Holly Springs

6:22 a.m. Monday

Review: Your 54 WRAL TechWire headlines from last week

Week in review Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with more than 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.

Updated 6:09 a.m. Monday

Have news? Share it with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

October 24

#WTWTrends for Friday: Ebola, Zuckerberg speaks Chinese, UNC, SA101, Seattle Shooting Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Friday, Oct. 24, 2014 as curated by @WRALTechWire.

Updated October 24

GSK exec on Ebola vaccine trial: 'We only have one shot to get this right'

Ebola The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?

October 22

Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

October 22

Premium Lock Viamet Pharma withdaws IPO, raises $60M, names Bob Ingram chairman

Viamet Pharmaceuticals scrapped its plans for a $75 million IPO on Tuesday. Instead, the Triangle-based company raised $60 million in new capital. At the same time Viamet named former Glaxo CEO Bob Ingram as its chairman and spun off a new venture focused on prostate cancer.

Robert Ingram Robert Ingram

October 21

GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll